Tag: UCB
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses ... Read More
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More
Amgen, UCB resubmit BLA of EVENITY osteoporosis drug to FDA
Amgen and UCB have resubmitted the biologics license application (BLA) of their investigational osteoporosis drug EVENITY (romosozumab) to the US Food and Drug Administration (FDA) ... Read More